Clinical Genomics partners with the Colorectal Cancer Alliance in the Life After Cancer Mission
BRIDGEWATER, N.J., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of cancer diagnostic solutions including liquid biopsy tests, today announced its partnership with the Colorectal Cancer Alliance in a yearlong collaboration for the Life After Cancer mission. The Alliance is the largest US-based nonprofit patient advocacy group for colorectal cancer patients, providing resources and education to patients in their fight against this disease. The Life After Cancer initiative focuses on helping patients navigate their survivorship path by creating awareness about recurrence monitoring as part of their follow up care, allowing those who have overcome the disease to become an advocate of their long-term health and well-being. This expanded partnership between Clinical Genomics and the Colorectal Cancer Alliance builds upon an existing relationship to continue the mission to support this patient community.
Clinical Genomics is the sole provider of COLVERA™, a unique blood test for patients who have been diagnosed with colorectal cancer (CRC) that identifies circulating tumor DNA (ctDNA) for early detection of residual and recurrent disease, at a stage when more treatment options are available for these patients. COLVERA is currently marketed in the USA and available through our CLIA-certified laboratory in Bridgewater, NJ.
“Early detection has been shown to improve overall survival from this deadly disease. Colorectal cancer affects a wide range of ages with increasing incidence in younger patients. Partnerships like this with Clinical Genomics are critical in order to make an impact on this devasting disease and provide patients with cutting edge tools and resources they need in order to navigate their choices,” stated Michael Sapienza, CEO of the Colorectal Cancer Alliance.
“We had the great pleasure to meet patients and their circle of support at the Alliance’s National Conference in Houston this year. Working with the Alliance on Life After Cancer, we can contribute to providing important education and awareness resources to this community. Colorectal cancer screening is an important focus in the US and now we must emphasize the importance of follow-up care surveillance monitoring of CRC with tests like COLVERA, for patients who have been diagnosed with the disease,” said Betsy Hanna, Chief Commercial Officer of Clinical Genomics.
About Colorectal Cancer Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer related deaths in the United States, with more than 140,000 people per year expected to be diagnosed with CRC and as many as 50,000 succumbing to the disease. For patients who survive, 30-50% will experience a recurrence, most within the first two to three years of primary treatment. On average, the lifetime risk of developing colorectal cancer is about one in 23 for men and women combined, however, this varies widely according to individual risk factors.
About Clinical GenomicsClinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing from screening to post-treatment monitoring. InSure® ONE™ is a one sample fecal immunochemical test used to detect lower GI bleeding for screening in healthy adults. COLVERA™ is a proprietary liquid biopsy blood test that identifies circulating tumor DNA for the detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management.
About the Colorectal Cancer AllianceThe Colorectal Cancer Alliance is a national nonprofit committed to ending colorectal cancer. Working with our nation of passionate allies, we diligently support the needs of patients and families, caregivers, and survivors; eagerly raise awareness of preventive screening; and continually strive to fund critical research. As allies in the struggle, we are fiercely determined to end colorectal cancer within our lifetime. For more information, visit ccalliance.org.
Clinical GenomicsPatty Jenkins email@example.com | (412) 980-1149
Colorectal Cancer AllianceSteven Bushon firstname.lastname@example.org | (330) 957-0484